WO2003018057A1 - Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 - Google Patents
Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 Download PDFInfo
- Publication number
- WO2003018057A1 WO2003018057A1 PCT/JP2002/007528 JP0207528W WO03018057A1 WO 2003018057 A1 WO2003018057 A1 WO 2003018057A1 JP 0207528 W JP0207528 W JP 0207528W WO 03018057 A1 WO03018057 A1 WO 03018057A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glaucoma
- kinase inhibitory
- administration
- intraocular pressure
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Definitions
- the present invention relates to a therapeutic agent for glaucoma comprising a compound having a PI3 kinase inhibitory activity as an active ingredient.
- Glaucoma is an intractable eye disease that raises intraocular pressure due to various factors and may lead to blindness, and various treatment methods are being studied. There are three treatments: drug therapy, laser therapy, and surgery.
- Pharmaceutical therapies include) 3 blockers, prostaglandin-related drugs, carbonic anhydrase inhibitors, cholinergic drugs, and epinephrine-related drugs.
- PI 3 kinase (phosphatidyl inositol 3-kinase, phosphatidyl inosiiol 3-kinase) is an enzyme that phosphorylates the hydroxyl group at the 3-position of the inositol ring in inositol phospholipids.
- To produce PI 3-kinase is a type I ⁇ !
- PI3 kinase A wide variety of roles have been reported for PI3 kinase, but the main ones are cell proliferation and cytoskeleton regulation by platelet-derived growth factor. Nodes, glucose metabolism by insulin, neurite outgrowth, involvement in immune cells. Phospholipids in which the hydroxyl group at position 3 of the inositol ring is phosphorylated by PI 3-kinase activate serine-threonine kinases such as PDK1 and Akt / PKB in receptor-stimulated signaling pathways Act as a second messenger. In addition, it plays an important role as a regulator of membrane transport.
- Japanese Patent Application Laid-Open No. 7-145501 discloses a PI3 kinase inhibitor.
- JP-T-Hei 9-5121253 discloses that a PI3 kinase inhibitor is useful for suppressing an immune response in organ transplantation and autoimmune diseases.
- a PI3 kinase inhibitor is useful for suppressing an immune response in organ transplantation and autoimmune diseases.
- the present inventors have conducted intensive studies on the effects of compounds having PI3 kinase inhibitory activity and found that compounds having PI3 kinase inhibitory activity have an intraocular pressure lowering effect. It showed potential as a candidate compound.
- the present invention relates to a therapeutic agent for glaucoma comprising a compound having a PI3 kinase inhibitory activity as an active ingredient.
- Examples of compounds having a PI3 kinase inhibitory activity in the present invention include wortmannin (Trorts Biochem. Sci., 20, 303-). 307, 1995), 2- (4-morpholinyl) -18-phenyl _ 4 H—1—benzopyran-14-one (LY 2 940 02; Japanese Patent Application Laid-Open No.
- the present invention is characterized by the fact that a compound having a PI3 kinase inhibitory effect exhibits an intraocular pressure-lowering effect irrespective of the chemical structure. It has no effect.
- the compound having a PI3 kinase inhibitory action can be administered orally or parenterally.
- the dosage form include tablets, capsules, granules, powders, eye drops, eye ointments, injections, etc., with eye drops, eye ointments and injections being particularly preferred. These can be formulated using commonly used techniques. Eye drops include isotonic agents such as sodium chloride and concentrated glycerin, buffers such as sodium phosphate and sodium acetate, polyoxyethylene sorbitan monolate, polyoxyethylene stearate 40, and polyoxyethylene cured.
- the present invention also relates to a method for treating glaucoma, which comprises administering to a patient an effective amount of a compound having a PI3 kinase inhibitory activity.
- the dose can be appropriately selected depending on the symptoms, age, etc., but the amount of the eye drops is 0.001 to 5% (w / v), preferably 0.01 to 3% (w / v), particularly preferably. 0.0 1 to 1% (w / v) should be instilled once or several times a day.
- the present invention also relates to the use of a compound having a PI3 kinase inhibitory effect for the manufacture of a therapeutic agent for glaucoma.
- Eye drops in 1 OmL
- an applanation tonometer or pneumatic applanation tonometer was used to measure intraocular pressure. A measurement was made.
- LY2940002 and wortmannin were prepared as test compounds.
- the former is dissolved in methanol to a concentration of 1 O-iM, 2-hydroxypropyl-1- ⁇ -cyclodextrin is added as a solubilizer, and this solution is diluted with physiological saline to a concentration of 10_3 3 .
- LY 2940 02 solution was obtained. 2
- the amount of hydroxypropyl-1- ⁇ -cyclodextrin used was such that its final concentration was 4x10-3 3 .
- Wortmannin was dissolved to a concentration in dimethyl sulfoxide is 1 0 for the anterior chamber administration test, concentration 1 0 4 M and 1 0 5 M This solution was diluted with saline Was obtained. Also for eye drop test It was dissolved at 1 0 and 0.04 2 84% in suspension state to (1 0_ 3 M) solution was prepared.
- Heron intraocular pressure measurement The tonometer (pneutonometer model 30 classic) was turned on and calibration was performed. A 30 G injection needle was attached to the micro syringe, and the test compound solution or base was inhaled. An aluminum heron retainer for administration into the anterior chamber was placed on an aluminum table. A wooden heron retainer was placed on an aluminum table for measuring intraocular pressure.
- ⁇ Eg in the anterior chamber of the heron The ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ heron was set in an aluminum ⁇ sagi retainer for anterior chamber administration, and one drop of 0.4% oxybupro hydrochloride was instilled in both eyes. After wearing the eyelid opener, hold the bulb conjunctiva with tweezers, pass the needle tip through the cornea limbus about 2-3 mm through the corneal stroma, then irritate into the anterior chamber, The test compound solution was injected at 20 ⁇ L. After injecting the test compound solution, the needle was removed slowly so that aqueous humor did not leak. After the administration, the heron was returned to the cage.
- Intracameral administration of monkeys ⁇ Same as heron administration. The dose was 10 ⁇ L, and the intraocular pressure measurement time was 1 hour before administration, immediately before administration, and 2, 4, and 6 hours after administration.
- Monkey ophthalmic test 20 L of the test compound solution was instilled into the administered eye. The administration time was 1 hour before administration, immediately before administration, and 2, 4, and 6 hours after administration.
- Table 1 shows the results when LY294002 was administered into the anterior chamber of the egret. As can be seen from Table 1, a decrease in intraocular pressure was observed after LY294002 administration. Maximum intraocular pressure Fuhaba (maximum value of the base-administered group and the test of compound administration group and ⁇ difference) is verified hour after 1 0- 3 M LY 2 940 02 administration 6, the value was 3. 7 mmHg.
- Table 2 shows the results obtained when wortmannin was administered into the anterior chamber of the egret. As can be seen from Table 2, a decrease in intraocular pressure was observed after Waltmannin injection. The maximum decrease in intraocular pressure was confirmed 6 hours after Waltmannin administration,
- Tables 3 and 4 show the results obtained when wortmannin was instilled in monkeys and administered into the anterior chamber. As can be seen from Table 3, a decrease in intraocular pressure after instillation of Waltmannin was observed, and the maximum decrease in intraocular pressure was 2.8 mmHg 4 hours after administration. On the other hand, in the anterior chamber administration, a decrease in the maximum intraocular pressure was confirmed 2 hours after administration, and the value was 4.5 mmHg. table 1
- Compounds having PI 3 kinase inhibitory activity have an excellent intraocular pressure lowering effect and are useful as therapeutic agents for glaucoma.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/484,752 US20040242545A1 (en) | 2001-07-26 | 2002-07-25 | Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect |
EP02751673A EP1417976A4 (en) | 2001-07-26 | 2002-07-25 | AGENT FOR TREATING GLAUKOM WITH A COMPOUND WITH PI3-KINASE INHIBITING EFFECT |
CA2454976A CA2454976C (en) | 2001-07-26 | 2002-07-25 | Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-225606 | 2001-07-26 | ||
JP2001225606 | 2001-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003018057A1 true WO2003018057A1 (fr) | 2003-03-06 |
Family
ID=19058571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/007528 WO2003018057A1 (fr) | 2001-07-26 | 2002-07-25 | Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20040242545A1 (ja) |
EP (1) | EP1417976A4 (ja) |
CA (1) | CA2454976C (ja) |
WO (1) | WO2003018057A1 (ja) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2879100B1 (fr) | 2004-12-09 | 2007-07-06 | Lionel Bueno | Compositions pour le traitement des pathologies oculaires de surface et de la retine |
WO2007127175A2 (en) | 2006-04-26 | 2007-11-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
AU2007329352B2 (en) | 2006-12-07 | 2013-01-17 | F. Hoffmann-La Roche Ag | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
US8007170B2 (en) * | 2007-09-04 | 2011-08-30 | Pepperl + Fuchs | Electronic sensor and method for the manufacture of a sensor |
CA2704711C (en) | 2007-09-24 | 2016-07-05 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
KR101195329B1 (ko) | 2007-12-19 | 2012-10-29 | 제넨테크, 인크. | 5-아닐리노이미다조피리딘 및 사용 방법 |
AU2008340247B2 (en) | 2007-12-21 | 2012-11-15 | Genentech, Inc. | Azaindolizines and methods of use |
KR102021728B1 (ko) | 2009-02-05 | 2019-09-16 | 이뮤노젠 아이엔씨 | 신규한 벤조디아제핀 유도체 |
US8536161B2 (en) | 2009-03-12 | 2013-09-17 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
EP2427174A4 (en) * | 2009-05-04 | 2014-01-15 | Santen Pharmaceutical Co Ltd | HEMMER OF THE MTOR SIGNAL PATH FOR THE TREATMENT OF EYE TROUBLE |
BR112012006802A2 (pt) | 2009-09-28 | 2020-08-18 | F.Hoffmann-La Roche Ag | composto, composição farmacêutica, método para tratar câncer, usos de um composto, kit e invenção |
WO2011049625A1 (en) | 2009-10-20 | 2011-04-28 | Mansour Samadpour | Method for aflatoxin screening of products |
KR101821768B1 (ko) | 2009-11-05 | 2018-01-24 | 리젠 파마슈티컬스 소시에떼 아노님 | 신규한 벤조피란 키나제 조절제 |
MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
WO2012112708A1 (en) | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
MY168757A (en) | 2011-05-04 | 2018-12-04 | Rhizen Pharmaceuticals S A | Novel compounds as modulators of protein kinases |
NZ702244A (en) | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
MX357043B (es) | 2012-07-04 | 2018-06-25 | Rhizen Pharmaceuticals Sa | Inhibidores selectivos de pi3k delta. |
WO2014031566A1 (en) | 2012-08-22 | 2014-02-27 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives |
US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
JP6494533B2 (ja) | 2013-02-28 | 2019-04-03 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤としてのマイタンシノイドを含む複合体 |
WO2014194030A2 (en) | 2013-05-31 | 2014-12-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
WO2015116735A1 (en) | 2014-01-28 | 2015-08-06 | Mayo Foundation For Medical Education And Research | Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders |
IL311537A (en) | 2014-01-28 | 2024-05-01 | Mayo Found Medical Education & Res | Methods and preparations for killing aging cells and for the treatment of diseases and disorders related to aging |
AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
EP3507305A1 (en) | 2016-09-02 | 2019-07-10 | Dana-Farber Cancer Institute, Inc. | Composition and methods of treating b cell disorders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03215423A (ja) * | 1990-01-18 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | 血管拡張剤 |
WO1995029673A1 (en) * | 1994-04-29 | 1995-11-09 | The United States Of America, Represented By The Secretary Of The Navy | Methods for modulating t cell responses by manipulating intracellular signal transduction |
WO2000027414A2 (en) * | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5504103A (en) * | 1993-08-25 | 1996-04-02 | Eli Lilly And Company | Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof |
AU777275B2 (en) * | 1999-07-02 | 2004-10-07 | Stuart A. Lipton | Method of reducing neuronal injury or apoptosis |
US6103756A (en) * | 1999-08-11 | 2000-08-15 | Vitacost Inc. | Ocular orally ingested composition for prevention and treatment of individuals |
DK1467761T3 (da) * | 2001-11-30 | 2007-02-05 | Quadra Logic Tech Inc | Behandling af neovaskulære oftalmiske sygdomme |
-
2002
- 2002-07-25 WO PCT/JP2002/007528 patent/WO2003018057A1/ja not_active Application Discontinuation
- 2002-07-25 CA CA2454976A patent/CA2454976C/en not_active Expired - Fee Related
- 2002-07-25 US US10/484,752 patent/US20040242545A1/en not_active Abandoned
- 2002-07-25 EP EP02751673A patent/EP1417976A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03215423A (ja) * | 1990-01-18 | 1991-09-20 | Kyowa Hakko Kogyo Co Ltd | 血管拡張剤 |
WO1995029673A1 (en) * | 1994-04-29 | 1995-11-09 | The United States Of America, Represented By The Secretary Of The Navy | Methods for modulating t cell responses by manipulating intracellular signal transduction |
WO2000027414A2 (en) * | 1998-11-06 | 2000-05-18 | Basf Aktiengesellschaft | Inhibition of the formation of vascular hyperpermeability |
Non-Patent Citations (1)
Title |
---|
YOUSUFZAI SARDAR Y.K. ET AL.: "Mitogen-activated protein kinase inhibitors suppress prostaglandin F2alpha-induced myosin-light chain phosphorylation and contraction in iris sphincter smooth muscle", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 407, no. 1-2, 2000, pages 17 - 26, XP002957380 * |
Also Published As
Publication number | Publication date |
---|---|
US20040242545A1 (en) | 2004-12-02 |
EP1417976A4 (en) | 2004-09-15 |
CA2454976A1 (en) | 2003-03-06 |
EP1417976A1 (en) | 2004-05-12 |
CA2454976C (en) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003018057A1 (fr) | Remede contre le glaucome contenant en tant qu'ingredient actif un compose presentant un effet inhibiteur de la kinase pi3 | |
RU2460526C2 (ru) | Профилактическое или терапевтическое средство для возрастной дегенерации желтого пятна | |
RU2406499C2 (ru) | Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений | |
EP0642789A1 (en) | Remedy for glaucoma | |
JP2008308489A (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
EP2319539A1 (en) | Prophylactic or therapeutic agent for axial myopia | |
WO2000018422A1 (fr) | Promoteurs de secretion lacrymale ou gouttes ophtalmologiques contenant des peptides natriuretiques comme principes actifs pour traiter la keratoconjonctivite | |
US5837723A (en) | Pharmaceutical composition useful for treating ophthalmological diseases | |
JP3527256B2 (ja) | 抗アレルギー点眼剤 | |
ES2354223T3 (es) | Derivados de amidina para uso en la prevención o el tratamiento de glaucoma. | |
JP2967523B2 (ja) | 眼病用製薬組成物 | |
EP1297849B1 (en) | Remedial agent for optic nerve diseases | |
US5519030A (en) | Method for prophylaxis and treatment of myopia | |
EP0565897B1 (en) | Argatroban preparations for ophthalmic use | |
CA2442296C (en) | Therapeutic agents for retinochoroidal disorders comprising steroids as active ingredients | |
JPH10500130A (ja) | テラゾシンを含有する緑内障治療用医薬組成物 | |
WO2005053678A1 (ja) | 虚血性神経障害治療又は予防剤 | |
WO2004075895A1 (ja) | 眼圧低下剤 | |
JP3530542B2 (ja) | 眼科用アルガトロバン製剤 | |
JP4456269B2 (ja) | 視神経乳頭循環改善剤 | |
JP4393863B2 (ja) | 視神経細胞保護剤 | |
JP2003104909A (ja) | Pi3キナーゼ阻害作用を有する化合物を有効成分とする緑内障治療剤 | |
Fallor et al. | Ocular toxicity of experimental intravitreal vitamin E | |
JP2004250347A (ja) | 網膜虚血に基づく疾患の治療および/又は予防剤 | |
JPH10316571A (ja) | 眼循環障害改善剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2454976 Country of ref document: CA Ref document number: 10484752 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002751673 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2002751673 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002751673 Country of ref document: EP |